Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

416 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Among authors: targan s. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.
Infliximab for the treatment of fistulas in patients with Crohn's disease.
Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ. Present DH, et al. Among authors: targan s. N Engl J Med. 1999 May 6;340(18):1398-405. doi: 10.1056/NEJM199905063401804. N Engl J Med. 1999. PMID: 10228190 Clinical Trial.
Long-term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy.
Sandborn WJ, Rutgeerts P, Gasink C, Jacobstein D, Zou B, Johanns J, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJS, Colombel JF, Feagan BG. Sandborn WJ, et al. Among authors: targan s. Aliment Pharmacol Ther. 2018 Jul;48(1):65-77. doi: 10.1111/apt.14794. Epub 2018 May 24. Aliment Pharmacol Ther. 2018. PMID: 29797519 Free PMC article. Clinical Trial.
Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease.
Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Cornillie F, et al. Among authors: targan sr. Aliment Pharmacol Ther. 2001 Apr;15(4):463-73. doi: 10.1046/j.1365-2036.2001.00956.x. Aliment Pharmacol Ther. 2001. PMID: 11284774 Clinical Trial.
An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial.
Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, Wolf DC, Baker JP, Hawkey C, Archambault A, Bernstein CN, Novak C, Heath PK, Targan SR; CDP571 Crohn's Disease Study Group. Sandborn WJ, et al. Among authors: targan sr. Gastroenterology. 2001 May;120(6):1330-8. doi: 10.1053/gast.2001.24042. Gastroenterology. 2001. PMID: 11313302 Clinical Trial.
416 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page